Extension Study Of Tanezumab In Osteoarthritis

Summary

Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab

Timeline

Start

2009-02-06

Primary completion

2010-11-02

Completion

2011-06-23

Outcome

Outcome not reported

Stopped: “See termination reason in detailed description.”

Publications

• Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, Smith MD, Hungerford DS. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. Arthritis Rheumatol. 2016 Feb;68(2):382-91. doi: 10.1002/art.39492.

Drugs

Indications